BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 29237699)

  • 1. Single inhaler triple therapy for COPD.
    Drug Ther Bull; 2017 Dec; 55(12):138-141. PubMed ID: 29237699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide.
    Singh D; Corradi M; Spinola M; Papi A; Usmani OS; Scuri M; Petruzzelli S; Vestbo J
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2917-2928. PubMed ID: 29062229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide as a combination therapy for chronic obstructive pulmonary disease.
    Kupczyk M; Kuna P
    Expert Rev Respir Med; 2019 Jan; 13(1):5-11. PubMed ID: 30463457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The TRIFLOW study: a randomised, cross-over study evaluating the effects of extrafine beclometasone/formoterol/glycopyrronium on gas trapping in COPD.
    Dean J; Panainte C; Khan N; Singh D
    Respir Res; 2020 Dec; 21(1):323. PubMed ID: 33298062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.
    Vestbo J; Papi A; Corradi M; Blazhko V; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Singh D
    Lancet; 2017 May; 389(10082):1919-1929. PubMed ID: 28385353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol.
    Rabe KF; Martinez FJ; Ferguson GT; Wang C; Singh D; Wedzicha JA; Trivedi R; St Rose E; Ballal S; McLaren J; Darken P; Reisner C; Dorinsky P
    Respir Med; 2019; 158():59-66. PubMed ID: 31605923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Fixed Triple Therapy with Beclometasone/Formoterol/Glycopyrronium on Health Status and Adherence in Chronic Obstructive Pulmonary Disease (COPD) in an Italian Context of Real Life: The TRITRIAL Study Protocol.
    Richeldi L; Piraino A; Macagno F; Micarelli G; Ingrassia E
    Int J Chron Obstruct Pulmon Dis; 2021; 16():159-166. PubMed ID: 33536751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
    Singh D; Papi A; Corradi M; Pavlišová I; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Vestbo J
    Lancet; 2016 Sep; 388(10048):963-73. PubMed ID: 27598678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study).
    Singh D; Schröder-Babo W; Cohuet G; Muraro A; Bonnet-Gonod F; Petruzzelli S; Hoffmann M; Siergiejko Z;
    Respir Med; 2016 May; 114():84-90. PubMed ID: 27109816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized study of the effects of Aerochamber Plus
    Fakih F; Spangenthal S; Sigal B; Darken P; Maes A; Siddiqui S; Gillen M; Reisner C; Martin UJ
    Respir Med; 2018 May; 138():74-80. PubMed ID: 29724397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD.
    Ferguson GT; Rodriguez-Roisin R; Reisner C; Maes A; Siddiqui S; Martin UJ
    Int J Chron Obstruct Pulmon Dis; 2018; 13():945-953. PubMed ID: 29606861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute cardiovascular safety of two formulations of beclometasone dipropionate/formoterol fumarate in COPD patients: A single-dose, randomised, placebo-controlled crossover study.
    Singh D; Ciurlia G; Piccinno A; Muraro A; Bocchi M; Scuri M
    Pulm Pharmacol Ther; 2017 Feb; 42():43-51. PubMed ID: 28065679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetics of three doses of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler compared with active controls: A Phase I randomized, single-dose, crossover study in healthy adults.
    Darken P; DePetrillo P; Reisner C; St Rose E; Dorinsky P
    Pulm Pharmacol Ther; 2018 Jun; 50():11-18. PubMed ID: 29544728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spotlight on glycopyrronium/formoterol fumarate inhalation aerosol in the management of COPD: design, development, and place in therapy.
    Dhungana S; Criner GJ
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2307-2312. PubMed ID: 28814858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular safety profile of a fixed-dose combination of glycopyrrolate and formoterol fumarate delivered via metered dose inhaler using co-suspension delivery technology.
    Ferguson GT; Reisner C; Pearle J; DePetrillo P; Maes A; Martin UJ
    Pulm Pharmacol Ther; 2018 Apr; 49():67-74. PubMed ID: 29567116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single inhaler triple therapy with extrafine beclomethasone, formoterol, and glycopyrronium for the treatment of chronic obstructive pulmonary disease.
    Singh D
    Expert Opin Pharmacother; 2018 Aug; 19(11):1279-1287. PubMed ID: 29985096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRICOP - A Real-world effectiveness study with a single-inhaler extrafine triple therapy over 52 weeks in Austrian patients with COPD.
    Marth K; Renner A; Pohl W
    Respir Med; 2021 Jun; 182():106398. PubMed ID: 33901786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and safety of a single dose of the novel LAMA/LABA fixed-dose combination of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler, formulated using co-suspension delivery technology, in Japanese healthy subjects.
    Reisner C; Miller J; DePetrillo P; Maes A; Siddiqui S; Martin UJ
    Pulm Pharmacol Ther; 2018 Dec; 53():33-38. PubMed ID: 30218695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of extrafine beclomethasone dipropionate-formoterol fumarate in COPD patients who are not "frequent exacerbators": a post hoc analysis of the FORWARD study.
    Singh D; Vezzoli S; Petruzzelli S; Papi A
    Int J Chron Obstruct Pulmon Dis; 2017; 12():3263-3271. PubMed ID: 29138555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhaled beclometasone dipropionate/formoterol fumarate extrafine fixed combination for the treatment of asthma.
    Crisafulli E; Zanini A; Pisi G; Pignatti P; Poli G; Scuri M; Chetta A
    Expert Rev Respir Med; 2016; 10(5):481-90. PubMed ID: 26938578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.